Pediatric Dermatology Basics: Epidermolysis Bullosa, Chronic Bullous Disease of Childhood, and Staphylococcal Scalded Skin

Conclusions

• Pediatric dermatology conditions that disrupt skin structure can be understood and managed better by linking their clinical features to the underlying molecular defects in the skin barrier and basement membrane.
• For epidermolysis bullosa, especially recessive dystrophic disease, defects in collagen VII and related adhesion proteins drive chronic blistering, wound formation, scarring, cancer risk, and early mortality.
• The arrival of multiple FDA-approved EB therapies marks a major shift away from purely supportive wound care toward treatments that can improve healing, reduce pain, and potentially alter disease course.
• Topical B-VEC can meaningfully improve dystrophic EB wounds and pain with acceptable safety, and its home application makes treatment more feasible for families.
• Birch triterpene topical gel is an effective, well-tolerated option for dystrophic and junctional EB that improves wound closure, decreases dressing burden, and appears not to increase cancer risk in treated areas.
• Ex vivo gene-corrected skin grafting with prademagene zamikeracel offers a powerful one-time treatment for selected recessive dystrophic EB wounds, though cost and limited access remain major barriers.
• Earlier intervention in EB may provide the greatest long-term benefit, and future work should explore whether treating inflammation, fibrosis, itch, and squamous cell carcinoma risk can further improve outcomes.
• Chronic bullous disease of childhood is often a clinically recognizable IgA-mediated blistering disorder that can respond well to dapsone, but treatment requires caution because serious methemoglobinemia can occur.
• Dupilumab may be a safer steroid-sparing alternative for some inflammatory blistering childhood conditions when standard immunosuppressants are undesirable or poorly tolerated.
• Staphylococcal scalded skin syndrome is best recognized clinically as a toxin-mediated disease with widespread tenderness and no mucosal involvement, and it is treated with antistaphylococcal antibiotics plus supportive skin care.
• Overall, the talk suggests that better mechanistic understanding, combined with new targeted therapies, is rapidly improving the outlook for several severe pediatric blistering disorders.